ULTRAGENYX PHARMACEUTICAL INC. Deferred Employee Stock Ownership Plan, Issuance of Shares or Sale of Treasury Shares
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Deferred Employee Stock Ownership Plan, Issuance of Shares or Sale of Treasury Shares of $10.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:TreasuryStockDeferredEmployeeStockOwnershipPlan · last filed 2026-08-05
- 2026-06-30: Deferred Employee Stock Ownership Plan, Issuance of Shares or Sale of Treasury Shares $10.00M.
- 2026-03-31: Deferred Employee Stock Ownership Plan, Issuance of Shares or Sale of Treasury Shares $10.00M.
- 2025-12-31: Deferred Employee Stock Ownership Plan, Issuance of Shares or Sale of Treasury Shares $8.00M.
- 2025-09-30: Deferred Employee Stock Ownership Plan, Issuance of Shares or Sale of Treasury Shares $7.99M.
| Period end | Deferred Employee Stock Ownership Plan, Issuance of Shares or Sale of Treasury Shares | Deferred Employee Stock Ownership Plan, Issuance of Shares or Sale of Treasury Shares as first filed |
|---|---|---|
| 2026-06-30 | $10.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $10.00M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $8.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $7.99M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $7.99M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $7.57M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $4.00M 10-K · filed 2026-02-18 | $3.59M 10-K · filed 2025-02-19 |
| 2024-09-30 | $3.56M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $3.40M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $3.33M 10-Q · filed 2024-05-03 | |
| 2023-12-31 | $432.00K 10-K · filed 2025-02-19 | |
| 2023-09-30 | $381.00K 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $381.00K 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $356.00K 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $0.00 10-K · filed 2024-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |